1
|
Yonemori K, Fujiwara K, Hasegawa K, Yunokawa M, Ushijima K, Suzuki S, Shikama A, Minobe S, Usami T, Kim JW, Kim BG, Wang PH, Chang TC, Yamamoto K, Han S, McKenzie J, Barresi G, Miura T, Makker V, Kim Y. 177O Lenvatinib plus pembrolizumab versus treatment of physician’s choice in patients with previously treated advanced endometrial cancer: Study 309/KEYNOTE-775 Asian subgroup. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.10.213] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/05/2022] Open
|
2
|
Oaknin A, Bosse TJ, Creutzberg CL, Giornelli G, Harter P, Joly F, Lorusso D, Marth C, Makker V, Mirza MR, Ledermann JA, Colombo N. Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 2022; 33:860-877. [PMID: 35690222 DOI: 10.1016/j.annonc.2022.05.009] [Citation(s) in RCA: 123] [Impact Index Per Article: 61.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2022] [Revised: 04/27/2022] [Accepted: 05/19/2022] [Indexed: 12/24/2022] Open
Affiliation(s)
- A Oaknin
- Gynaecologic Cancer Programme, Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain
| | - T J Bosse
- Departments of Pathology, Leiden University Medical Center, Leiden, The Netherlands
| | - C L Creutzberg
- Radiation Oncology, Leiden University Medical Center, Leiden, The Netherlands
| | - G Giornelli
- Department of Oncology, Instituto Alexander Fleming, Buenos Aires, Argentina
| | - P Harter
- Department of Gynecology & Gynecologic Oncology, Ev. Kliniken Essen-Mitte, Essen, Germany
| | - F Joly
- ANTICIPE, Cancer and Cognition Platform, Normandie University, Caen, France; Medical Oncology Department, Centre François Baclesse, Caen, France
| | - D Lorusso
- Department of Life Science and Public Health, Catholic University of Sacred Heart, Largo Agostino Gemelli, Rome, Italy; Department of Women and Child Health, Division of Gynaecologic Oncology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy
| | - C Marth
- Department of Obstetrics and Gynecology, Medical University Innsbruck, Innsbruck, Austria
| | - V Makker
- Gynecologic Medical Oncology Service, Memorial Sloan Kettering Cancer Center, New York, USA; Department of Medicine, Weill Cornell Medical College, New York, USA
| | - M R Mirza
- Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
| | - J A Ledermann
- Cancer Institute, University College London (UCL), London, UK; Department of Oncology, UCL Hospitals, London, UK
| | - N Colombo
- Department of Gynecologic Oncology, Istituto Europeo di Oncologia IRCCS, Milan, Italy; Department of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy
| |
Collapse
|
3
|
Lorusso D, Colombo N, Casado Herraez A, Santin A, Colomba E, Miller D, Fujiwara K, Pignata S, Baron-Hay S, Ray-Coquard I, Shapira-Frommer R, Kim Y, McCormack M, Massaad R, Martin Nguyen A, Zhao Q, McKenzie J, Prabhu V, Makker V. 20MO Time to deterioration in quality of life in patients (pts) with advanced endometrial cancer (aEC) treated with lenvatinib plus pembrolizumab (L+P) or treatment of physician’s choice (TPC). Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.04.038] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
4
|
Vergote I, Fidalgo AP, Hamilton E, Valabrega G, Van Gorp T, Sehouli J, Cibula D, Levy T, Welch S, Richardson D, Alía EG, Scambia G, Henry S, Wimberger P, Miller D, Martínez J, Monk B, Shacham S, Mirza M, Makker V. VP2-2022: Prospective double-blind, randomized phase III ENGOT-EN5/GOG-3055/SIENDO study of oral selinexor/placebo as maintenance therapy after first-line chemotherapy for advanced or recurrent endometrial cancer. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.02.223] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
5
|
Colombo N, Lorusso D, Herráez AC, Santin A, Colomba E, Miller D, Fujiwara K, Pignata S, Floquet A, Monk B, Banerjee S, Penson R, Kristeleit R, Fabbro M, Orlando M, Mackay H, Jensen E, Dutta L, Orlowski R, Makker V. 726MO Outcomes by histology and prior therapy with lenvatinib plus pembrolizumab vs treatment of physician’s choice in patients with advanced endometrial cancer (Study 309/KEYNOTE-775). Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.1169] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
6
|
Makker V, Taylor M, Aghajanian C, Cohn A, Brose M, DiSimone C, Cao A, Suttner L, Loboda A, Cristescu R, Jelinic P, Snyder A, Nebozhyn M, Lunceford J, Orlowski R, Dutta L, Matsui J, Dutcus C, Minoshima Y, Messing M. 796P Association between biomarkers and clinical outcomes of lenvatinib (L) + pembrolizumab (P) in advanced endometrial cancer (EC): Results from KEYNOTE-146/study 111. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.1238] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
7
|
Jhaveri KL, Wang XV, Makker V, Luoh SW, Mitchell EP, Zwiebel JA, Sharon E, Gray RJ, Li S, McShane LM, Rubinstein LV, Patton D, Williams PM, Hamilton SR, Conley BA, Arteaga CL, Harris LN, O'Dwyer PJ, Chen AP, Flaherty KT. Corrigendum to 'Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q': [Annals of Oncology 30 (2019) 1821-1830]. Ann Oncol 2021; 32:1068. [PMID: 34099371 PMCID: PMC8929237 DOI: 10.1016/j.annonc.2021.05.797] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/04/2022] Open
Affiliation(s)
- K L Jhaveri
- Department of Medicine, Memorial Sloan-Kettering Center, New York, USA.
| | - X V Wang
- Biostatistics, E-A Biostatistical Center, Boston, USA
| | - V Makker
- Gynecologic Medical Oncology Service, Memorial Sloan-Kettering Cancer Center, New York, USA
| | - S-W Luoh
- Knight Cancer Institute, Oregon Health Science University, Portland, USA
| | - E P Mitchell
- Medical Oncology, Thomas Jefferson University, Philadelphia, USA
| | - J A Zwiebel
- Investigational Drug Branch, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, USA
| | - E Sharon
- Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, USA
| | - R J Gray
- Department of Biostatistics, Dana Farber Cancer Institutes, Boston, USA
| | - S Li
- Department of Biostatistics, Dana Farber Cancer Institutes, Boston, USA
| | - L M McShane
- Biometric Research Branch, National Cancer Institute, Bethesda, USA
| | - L V Rubinstein
- Biometric Research Branch, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institute of Health, Bethesda, USA
| | - D Patton
- Center for Biomedical, Informatics & Information Technology, National Cancer Institute, Bethesda, USA
| | - P M Williams
- Molecular Characterization Laboratory, Frederick National Laboratory for Cancer Research, Frederick, USA
| | - S R Hamilton
- Department of Pathology, University of Texas MD Anderson Cancer Center, Houston, USA
| | - B A Conley
- Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, USA
| | - C L Arteaga
- Department of Internal Medicine, University of Texas Southwestern, Dallas, USA
| | - L N Harris
- Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, USA
| | - P J O'Dwyer
- University of Pennsylvania, Philadelphia, USA
| | - A P Chen
- CTEP, National Cancer Institute, Bethesda, USA
| | - K T Flaherty
- Cancer Center, Massachusetts General Hospital, Boston, USA
| |
Collapse
|
8
|
Marth C, Vulsteke C, Rubio M, Makker V, Braicu E, McNeish I, Madry R, Ayhan A, Hasegawa K, Wu X, Dutta L, Xu C, Keefe S, Lee J, Pignata S. ENGOT-en9/LEAP-001: A phase III, randomized, active-controlled, open-label study of pembrolizumab plus lenvatinib versus paclitaxel plus carboplatin for newly diagnosed advanced or recurrent endometrial cancer. Gynecol Oncol 2020. [DOI: 10.1016/j.ygyno.2020.05.366] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
9
|
Makker V, Rasco D, Vogelzang N, Brose M, Cohn A, Mier J, DiSimone C, Hyman D, Stepan D, Dutcus C, Schmidt E, Guo M, Sachdev P, Shumaker R, Aghajanian C, Taylor M. Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: Final analysis of a multicentre, open-label, single-arm, phase 2 trial. Gynecol Oncol 2020. [DOI: 10.1016/j.ygyno.2020.06.012] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
10
|
Nobre SP, Ataseven B, Bois A, Makker V, Alektiar K, Leitao M, Abu-Rustum N, Mueller J. Impact of adjuvant therapy on oncologic outcomes in early-stage uterine clear cell carcinoma. Gynecol Oncol 2020. [DOI: 10.1016/j.ygyno.2020.05.591] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
11
|
Jhaveri KL, Wang XV, Makker V, Luoh SW, Mitchell EP, Zwiebel JA, Sharon E, Gray RJ, Li S, McShane LM, Rubinstein LV, Patton D, Williams PM, Hamilton SR, Conley BA, Arteaga CL, Harris LN, O'Dwyer PJ, Chen AP, Flaherty KT. Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q. Ann Oncol 2019; 30:1821-1830. [PMID: 31504139 PMCID: PMC6927318 DOI: 10.1093/annonc/mdz291] [Citation(s) in RCA: 87] [Impact Index Per Article: 17.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022] Open
Abstract
BACKGROUND The National Cancer Institute-Molecular Analysis for Therapy Choice (NCI-MATCH) is a national precision medicine study incorporating centralized genomic testing to direct refractory cancer patients to molecularly targeted treatment subprotocols. This treatment subprotocol was designed to screen for potential signals of efficacy of ado-trastuzumab emtansine (T-DM1) in HER2-amplified histologies other than breast and gastroesophageal tumors. METHODS Eligible patients had HER2 amplification at a copy number (CN) >7 based on targeted next-generation sequencing (NGS) with a custom Oncomine AmpliSeq™ (ThermoFisher Scientific) panel. Patients with prior trastuzumab, pertuzumab or T-DM1 treatment were excluded. Patients received T-DM1 at 3.6 mg/kg i.v. every 3 weeks until toxicity or disease progression. Tumor assessments occurred every three cycles. The primary end point was centrally assessed objective response rate (ORR). Exploratory end points included correlating response with HER2 CN by NGS. The impact of co-occurring genomic alterations and PTEN loss by immunohistochemistry were also assessed. RESULTS Thirty-eight patients were enrolled and 36 included in efficacy analysis. Median prior therapies in the metastatic setting was 3 (range 0-9; unknown in one patient). Median HER2 CN was 17 (range 7-139). Partial responses were observed in two (5.6%) patients: one mucoepidermoid carcinoma of parotid gland and one parotid gland squamous cell cancer. Seventeen patients (47%) had stable disease including 8/10 (80%) with ovarian and uterine carcinomas, with median duration of 4.6 months. The 6-month progression-free survival rate was 23.6% [90% confidence interval 14.2% to 39.2%]. Common toxicities included fatigue, anemia, fever and thrombocytopenia with no new safety signals. There was a trend for tumor shrinkage with higher levels of gene CN as determined by the NGS assay. CONCLUSION T-DM1 was well tolerated. While this subprotocol did not meet the primary end point for ORR in this heavily pre-treated diverse patient population, clinical activity was seen in salivary gland tumors warranting further study in this tumor type in dedicated trials.
Collapse
Affiliation(s)
- K L Jhaveri
- Department of Medicine, Memorial Sloan-Kettering Center, New York.
| | - X V Wang
- Biostatistics, E-A Biostatistical Center, Boston
| | - V Makker
- Gynecologic Medical Oncology Service, Memorial Sloan-Kettering Cancer Center, New York
| | - S-W Luoh
- Knight Cancer Institute, Oregon Health Science University, Portland
| | - E P Mitchell
- Medical Oncology, Thomas Jefferson University, Philadelphia
| | - J A Zwiebel
- Investigational Drug Branch, Division of Cancer Treatment and Diagnosis
| | - E Sharon
- Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda
| | - R J Gray
- Department of Biostatistics, Dana Farber Cancer Institutes, Boston
| | - S Li
- Department of Biostatistics, Dana Farber Cancer Institutes, Boston
| | - L M McShane
- Biometric Research Branch, National Cancer Institute, Bethesda
| | - L V Rubinstein
- Biometric Research Branch, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institute of Health, Bethesda
| | - D Patton
- Center for Biomedical, Informatics & Information Technology, National Cancer Institute, Bethesda
| | - P M Williams
- Molecular Characterization Laboratory, Frederick National Laboratory for Cancer Research, Frederick
| | - S R Hamilton
- Department of Pathology, University of Texas MD Anderson Cancer Center, Houston
| | - B A Conley
- Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda
| | - C L Arteaga
- Department of Internal Medicine, University of Texas Southwestern, Dallas
| | - L N Harris
- Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda
| | | | - A P Chen
- CTEP, National Cancer Institute, Bethesda
| | - K T Flaherty
- Cancer Center, Massachusetts General Hospital, Boston, USA
| |
Collapse
|
12
|
Makker V, Taylor M, Aghajanian C, Oaknin A, Mier J, Cohn A, Marin MR, Lorenzo RB, Brose M, DiSimone C, Messing M, Stepan D, Dutcus C, Wu J, Schmidt E, Orlowski R, Sachdev P, Shumaker R, Herraez AC. Lenvatinib (LEN) and pembrolizumab (PEMBRO) in advanced endometrial cancer (EC). Ann Oncol 2019. [DOI: 10.1093/annonc/mdz250.002] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
13
|
Lee CH, Shah A, Makker V, Taylor M, Shaffer D, Hsieh J, Cohn A, DiSimone C, Marin AP, Rasco D, Ribe S, Richards D, Stepan D, Dutcus C, Wu J, Schmidt E, Perini R, Motzer R. Phase II study of lenvatinib plus pembrolizumab for disease progression after PD-1/PD-L1 immune checkpoint inhibitor in metastatic clear cell renal cell carcinoma (mccRCC): Results of an interim analysis. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz253.013] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
14
|
Marth C, Vulsteke C, Rubio M, Makker V, Braicu E, McNeish I, Radoslaw M, Ayhan A, Hasegawa K, Wu X, Dutta L, Xu C, Keefe S, Lee J, Pignata S. ENGOT-EN9/LEAP-001: A phase III, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz250.071] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
15
|
Moukarzel L, Stylianou A, Wu M, Nobre S, Abu-Rustum N, Broach V, Giri D, Iyengar N, Weigelt B, Makker V. Prospective study evaluating white adipose tissue inflammation and clinicopathologic features in endometrial cancer. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz250.050] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
16
|
Tunnage I, Stasenko M, Ashley C, Rubinstein M, Latham A, Mueller J, Leitao M, Friedman C, Makker V, Soslow R, Weigelt B, DeLair D, Hyman D, Aghajanian C, Abu-Rustum N, Cadoo K. Clinical outcomes of patients with pole mutated endometrioid endometrial cancer. Gynecol Oncol 2019. [DOI: 10.1016/j.ygyno.2019.03.126] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
17
|
Nobre SP, Zhou Q, Iasonos A, Chi D, Makker V, Alektiar K, Abu-Rustum N, Leitao M, Mueller J. Surgical cytoreduction in stage IVB serous endometrial carcinoma. Gynecol Oncol 2019. [DOI: 10.1016/j.ygyno.2019.04.567] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
18
|
Makker V, Boucicaut N, Cadoo K, Grisham R, Hyman D, O'Cearbhail R, Snyder Charen A, Tew W, Martin M, Aghajanian C. A phase 1 study of selinexor (S) in combination with paclitaxel (P) and carboplatin (C) in patients (pts) with advanced ovarian (OC) or endometrial cancers (EC). Ann Oncol 2017. [DOI: 10.1093/annonc/mdx372.041] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
19
|
Lee CH, Makker V, Rasco D, Taylor M, Dutcus C, Shumaker R, Schmidt E, Stepan D, Li D, Motzer R. A phase 1b/2 trial of lenvatinib plus pembrolizumab in patients with renal cell carcinoma. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx371.002] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
20
|
Schlappe B, Schiavone M, DeLair D, Ducie J, Eriksson A, Zivanovic O, Makker V, Soslow R, Abu-Rustum N, Leitao M. Clinical behavior of FIGO stage I endometrioid endometrial adenocarcinoma diagnosed as high-grade on preoperative biopsy and low-grade on hysterectomy specimen. Gynecol Oncol 2017. [DOI: 10.1016/j.ygyno.2017.03.241] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
21
|
Drilon A, Garralda E, Stathis A, Szyldergemajn S, Hyman D, Boni V, Griguolo G, Martinez EJ, Makker V, Canziani L, Teruel CF, Soto-Matos A, Sessa C, Calvo E. Lurbinectedin (PM01183) plus paclitaxel (P), recommended dose (RD) expansion results with or without the addition of bevacizumab (Bev) in patients (pts) with selected solid tumors. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw368.34] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
22
|
Voss M, Gordon M, Mita M, Rini B, Makker V, Macarulla T, Smith D, Kwak E, Cervantes A, Puzanov I, Pili R, Wang D, Jalal S, Pant S, Patel M, Neuwirth R, Zohren F, Infante J. 354 Phase I study of investigational oral mTORC1/2 inhibitor MLN0128: Expansion phase in patients with renal, endometrial, or bladder cancer. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)30217-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
23
|
Garralda E, Stathis A, Drilon A, Boni V, Hyman D, Calvo E, Griguolo G, Makker V, Doger B, Canziani L, Varghese A, Jimenez E, Luque J, Soto-Matos A, Szyldergemajn S, Sessa C. 335 Lurbinectedin (PM01183) in combination with paclitaxel (P) in patients (pts) with advanced solid tumors. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)30199-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
24
|
Schiavone M, Zivanovic O, Zhou Q, Leitao M, Alektiar K, Makker V, Iasonos A, Abu-Rustum N. Survival in patients with uterine carcinosarcoma undergoing sentinel lymph node mapping. Gynecol Oncol 2015. [DOI: 10.1016/j.ygyno.2015.01.500] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
25
|
Desai N, Kollmeier M, Makker V, Abu-Rustum N, Barakat R, Alektiar K. Comparison of Early-Stage Uterine Papillary Serous Carcinoma (UPSC) and Carcinosarcoma Treated With Adjuvant Carboplatin/Taxane Chemotherapy and Intravaginal Radiation Therapy (IVRT). Int J Radiat Oncol Biol Phys 2014. [DOI: 10.1016/j.ijrobp.2014.05.1532] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
26
|
Garcia A, Makker V, Spitz D, Matei D, Nick A, Landen C, Alvarez E, Mendelson D, Strother R, Seon B, Alvarez D, Adams B, Theuer C, Gordon M. Trc105 (Anti-Endoglin Antibody) in Combination with Bevacizumab (Bev) and As a Single Agent for Platinum Resistant Ovarian Cancer. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu338.13] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
27
|
Leitao M, Ducie J, Makker V, Barakat R, Aghajanian C, Gardner G, Alektiar K, Abu-Rustum N. Combined modality adjuvant therapy for FIGO stage IIIC endometrial carcinomas. Gynecol Oncol 2014. [DOI: 10.1016/j.ygyno.2014.03.355] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
28
|
Kim C, Kou L, Yu C, Taylor J, Zivanovic O, Barakat R, Makker V, Kattan M, Chi D. Nomogram predicting 5-year progression-free survival after secondary surgical cytoreduction for platinum-sensitive recurrent ovarian cancer. Gynecol Oncol 2014. [DOI: 10.1016/j.ygyno.2014.03.267] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
29
|
Desai N, Kiess A, Kollmeier M, Abu-Rustum N, Makker V, Barakat R, Alektiar K. Patterns of Relapse in Stage I-II Uterine Papillary Serous Carcinoma Treated With Adjuvant Intravaginal Radiation (IVRT). Int J Radiat Oncol Biol Phys 2013. [DOI: 10.1016/j.ijrobp.2013.06.1115] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
30
|
Kim C, Khoury-Collado F, Barber E, Soslow R, Makker V, Leitao M, Sonoda Y, Chi D, Barakat R, Abu-Rustum N. Sentinel lymph node mapping: A valuable tool for assessing nodal metastasis in low grade endometrial cancer with superficial myoinvasion. Gynecol Oncol 2013. [DOI: 10.1016/j.ygyno.2013.04.081] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
31
|
Kiess A, Damast S, Makker V, Kollmeier M, Gardner G, Abu-Rustum N, Barakat R, Alektiar K. PO-252 ADJUVANT CARBOPLATIN/PACLITAXEL AND INTRAVAGINAL RADIATION FOR STAGE I-II SEROUS ENDOMETRIAL CANCER. Radiother Oncol 2012. [DOI: 10.1016/s0167-8140(12)72218-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
32
|
Teckie S, Makker V, Tabar V, Shi W, Zhang Z, Aghajanian C, Beal K. Predictors of Survival in Ovarian Cancer Brain Metastases. Int J Radiat Oncol Biol Phys 2011. [DOI: 10.1016/j.ijrobp.2011.06.771] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/16/2022]
|
33
|
Khalil SS, Dos Santos LA, Zivanovic O, Abu-Rustum N, Soslow RA, Alektiar KM, Sabbatini P, Makker V, Jewell EL, Gardner GJ, Barakat RR, Leitao MM. Extent of lymphadenectomy in patients with node-positive (FIGO stage IIIC) endometrial carcinoma. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.e15566] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
34
|
Makker V, Abu-Rustum NR, Aghajanian CA, Hensley ML. Outcomes of adjuvant platinum-based chemotherapy or radiation therapy in completely resected stage I-IV uterine carcinosarcoma (uCS). J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.5560] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|